Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares hit a new 52-week high during trading on Monday . The company traded as high as $17.80 and last traded at $17.50, with a volume of 122,557 shares changing hands. The stock had previously closed at $17.43.

A number of research analysts recently commented on AMPH shares. Needham & Company LLC decreased their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, May 10th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 14th. Finally, BMO Capital Markets started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, June 28th. They issued a “market perform” rating and a $17.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Amphastar Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.80.

The firm has a market cap of $765.06 million and a PE ratio of 8530.00. The stock has a 50-day moving average price of $16.22 and a 200 day moving average price of $13.33.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.15. During the same quarter in the prior year, the business earned ($0.01) earnings per share. The business had revenue of $59.40 million for the quarter, compared to analyst estimates of $62 million. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Equities research analysts expect that Amphastar Pharmaceuticals Inc. will post $0.13 earnings per share for the current year.

In related news, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $16.00, for a total transaction of $36,752.00. Following the transaction, the chief financial officer now directly owns 66,949 shares of the company’s stock, valued at $1,071,184. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 7,500 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $15.94, for a total transaction of $119,550.00. Following the transaction, the director now directly owns 29,086 shares in the company, valued at $463,630.84. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Amphastar Pharmaceuticals stock. Russell Frank Co boosted its position in shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 289.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,965 shares of the company’s stock after buying an additional 62,407 shares during the period. Russell Frank Co owned 0.19% of Amphastar Pharmaceuticals worth $1,204,000 as of its most recent SEC filing.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.